Although there is not a commercially available vaccine for<unk> , there are several ongoing vaccine development programs. A new recombinant live-attenuated tetravalent<unk>  vaccine (CYD-TDV) has been investigated for efficacy and safety in a phase III randomized, observer-masked, placebo-controlled, multicenter trial in countries of the Asia-Pacific region.  The phase III clinical trial revealed that the novel<unk>  vaccine is safe and efficacious.
Dengue fever future or investigational therapies
Chikungunya future or investigational therapies
Marburg hemorrhagic fever medical therapy
Zika virus infection medical therapy
Lassa fever medical therapy
Lassa fever future or investigational therapies
Malaria future or investigational therapies
Bourbon virus infection secondary prevention